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The field of mitochondrial medicine is
rapidly transitioning from preclinical
observation to clinical application. Trans-
lation of promising data obtained in
mouse models is not always straight-
forward, however. Building on their own
work showing that a ketogenic diet
induces mitochondrial biogenesis and
delays the onset of disease in the Deletor
mouse, Ahola et al administered modified
Atkins diet (mAD) to five patients with
mitochondrial myopathy caused by mito-
chondrial DNA deletions (Ahola et al,
2016). Surprisingly, mAD did not induce
mitochondrial biogenesis in patients, but
rather triggered the progressive damage
of muscle cells, particularly those with
impaired respiratory chain activity (the
ragged-red fibres). The subsequent exten-
sive characterisation of the metabolic and
molecular profile changes observed in
patients and healthy controls provides a
significant advance towards understand-
ing the feasibility of dietary modification
as a treatment strategy for mitochondrial
diseases.
See also: S Ahola et al (November 2016)
M yopathy is a recurrent feature ofmitochondrial disorders, a groupof highly heterogeneous genetic
syndromes directly or indirectly related to
impaired respiratory chain function (Zeviani
& Di Donato, 2004). Progressive external
ophthalmoplegia (PEO) is the most common
clinical manifestation of mitochondrial
disease. Exercise intolerance and fatigue are
commonly associated with PEO and
frequently have a significant impact on the
quality of life of patients (Chinnery, 2015).
There are no approved effective therapies
available for mitochondrial diseases and
clinical management is largely supportive,
although a number of vitamins and co-
factors are often prescribed (Viscomi et al,
2015). The majority of interventions
proposed have been applied to genetically
heterogeneous cohorts of patients with
limited pre- and post-treatment molecular
and metabolic characterisation. In this issue
of EMBO Molecular Medicine, Ahola and
colleagues address this important issue by
extensively detailing the pathological, meta-
bolic and transcriptomic consequences of a
ketogenic (high fat, low carbohydrate) modi-
fied Atkins diet (mAD) in both healthy
subjects and a small cohort of patients with
PEO and exercise intolerance caused by
single or multiple mitochondrial DNA
(mtDNA) deletions (Ahola et al, 2016).
Despite uncertainty surrounding the
precise mechanism, ketogenic diet (KD) has
been used since the 1920s to treat seizures
in drug-resistant epilepsy (Paoli et al, 2013),
including Alpers–Huttenlocher syndrome, a
severe encephalopathy in patients harbour-
ing mutations in the mtDNA polymerase
gamma, POLG, gene (Joshi et al, 2009).
Preclinical evidence to support the beneficial
effects of a KD in mitochondrial disease
includes the discovery that ketogenic
medium kills cybrid cell lines carrying 100%
deleted mtDNA and reduces the amount of
deleted mtDNA in heteroplasmic lines
(Santra et al, 2004). Furthermore, KD has
been proven to induce mitochondrial
biogenesis and slow down disease progres-
sion in the Deletor mouse, which develops a
gradually progressive myopathy due to
mutant form of the mitochondrial helicase
TWINKLE (Ahola-Erkkila et al, 2010).
mAD induces ketosis, a metabolic state
characterised by the production of ketone
bodies from acetyl-CoA. Acetyl-CoA accu-
mulation results from reduced availability of
oxaloacetate, which is diverted towards
hepatic gluconeogenesis when dietary
glucose is restricted. Ketone bodies are
released into the bloodstream and re-
uptaken by non-gluconeogenic tissues, such
as the brain, where oxaloacetate is available,
and where they are subsequently re-
converted into acetyl-CoA entering the Krebs
cycle (Owen et al, 1967).
The five patients with mitochondrial
disease presented by Ahola et al (2016)
unexpectedly developed acute muscle
damage with burning sensation and muscle
pain spreading from their lower limbs to the
back, with elevated creatine kinase (CK),
transaminases and myoglobin levels within
days from initiating the mAD regimen,
unlike their age- and sex-matched controls
(Fig 1). Cessation of the mAD quickly
reversed these symptoms. Further investiga-
tions revealed that mAD induced selective
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necrotic degeneration of ragged-red fibres
(RRF) in PEO patients, without significant
changes in the background levels of apopto-
sis and autophagy or further activation of
satellite cells. No toxic effect was observed
in muscle fibres of healthy individuals.
Perhaps even more surprisingly, at 2.5-
year follow-up muscle strength had mildly
improved in three of four patients. Unfortu-
nately, muscle tissue was unavailable for
further evaluation at this time point. Never-
theless, the analysis of the metabolic and
molecular changes occurring during the acute
phase in patients and controls is highly infor-
mative. First, as a result of impaired respira-
tory chain function, the metabolism of
patients with PEO relied heavily on glucose,
as indicated by their high lactate levels. In
addition, lipids could not be utilised and
therefore accumulated in the liver, visceral
depots and skeletal muscle tissue. Introduc-
tion of the mAD regimen increased plasma
b-hydroxybutyrate levels similarly in both
controls and patients, suggesting comparable
ketosis induction in both groups. However,
due to the patients’ inability to catabolise
ketone bodies, a metabolic crisis appeared to
be triggered within their muscle tissue.
Second, patients and controls responded with
similar metabolic profiles to the switch from
an isocaloric to a high-fat, low-carbohydrate
diet. Increased plasma ammonium, a marker
of amino acid consumption for energy
production, and reduction in body weight
and fat depots were similar in patients and
controls. Third, transcriptomic analysis
demonstrated mAD increased mitochondrial
biogenesis, in addition to pathways related to
lipid utilisation, in control muscle. Contrari-
wise, these pathways were blunted in the
muscle tissue of patients with PEO whose
mitochondria were unable to metabolise
lipids, while pathways related to inflamma-
tion were activated in agreement with ongo-
ing damage. Finally, metabolomic profiling
revealed that patients and controls responded
similarly to mAD by increasing the carnitine
carrier pool and upregulating alternative
pathways in order to generate energy, such as
the branched chain amino acids. Notably,
alanine, a biomarker of mitochondrial
disease, and other disease-associated metabo-
lites, such as asparagine and xanthine, were
normalised by mAD.
Interestingly, unlike the reported human
study, a short-term ketogenic diet in the
Deletor mice revealed no signs of muscle
degeneration or creatine kinase elevation,
suggesting that mice with mitochondrial
disease have the metabolic capacity to adapt
more readily to dietary changes than
humans.
This study significantly advances current
knowledge concerning the molecular, cellu-
lar and systemic adaptations which occur in
the tissues of PEO patients, emphasises the
concept that any dietary intervention in
mitochondrial disease necessitates careful
clinical evaluation and laboratory monitor-
ing, and reaffirms the caution required when
extrapolating animal data to human studies.
Analysis of muscle tissue obtained after
2.5 years would have been extremely infor-
mative in further understanding the progres-
sion of mitochondrial disease after mAD and
would have clarified a number of important
questions which remain unanswered: Is there
a clear and persistent reduction in RRF? If so
what is the mechanism for this phenomenon?
Does muscle regeneration occur via activation
of muscle satellite cells? Although the latter
seems unlikely given the data obtained during
the acute phase of the study, it remains possi-
ble that over time satellite cells replace the
necrotic muscle fibres, thus explaining the
observed clinical amelioration. In support of
this possibility is the reported evidence that
satellite cells have lower levels of deleted
mtDNA molecules compared to the fully dif-
ferentiated myocytes and, once activated, can
proliferate and fuse with existing muscle
fibres replacing damaged cells (Moraes et al,
1989; Clark et al, 1997). In conclusion, this
study implies that mAD potentially represents
an effective strategy to initiate the selective
death of RRF, with subsequent replacement
of necrotic fibres by healthy muscle tissue
generated from satellite cells.
Further work is warranted to determine
whether repeated cycles of mAD could bene-
fit patients via selective elimination of defec-
tive muscle fibres.
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Figure 1. Main changes induced by mAD in myopathic patients.
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